|
|
Volumn 347, Issue , 2013, Pages
|
|
Avastin is as effective as Lucentis in treating wet age related macular degeneration, study finds.
a
a
NONE
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
ANGIOGENESIS INHIBITOR;
BEVACIZUMAB;
MONOCLONAL ANTIBODY;
RANIBIZUMAB;
COMPARATIVE STUDY;
COST BENEFIT ANALYSIS;
DRUG COST;
DRUG EFFECT;
ECONOMICS;
EXUDATIVE MACULAR DEGENERATION;
HUMAN;
INJECTION;
NATIONAL HEALTH SERVICE;
NOTE;
RANDOMIZED CONTROLLED TRIAL (TOPIC);
STATISTICS;
TREATMENT OUTCOME;
UNITED KINGDOM;
VISUAL ACUITY;
ANGIOGENESIS INHIBITORS;
ANTIBODIES, MONOCLONAL, HUMANIZED;
COST-BENEFIT ANALYSIS;
DRUG COSTS;
GREAT BRITAIN;
HUMANS;
INJECTIONS;
RANDOMIZED CONTROLLED TRIALS AS TOPIC;
STATE MEDICINE;
TREATMENT OUTCOME;
VISUAL ACUITY;
WET MACULAR DEGENERATION;
|
|
EID: 84884174219
PISSN: None
EISSN: 17561833
Source Type: Journal
DOI: 10.1136/bmj.f4678 Document Type: Note |
|
Times cited : (2)
|
|
References (0)
|
